Citi Raises HUTCHMED TP to HKD45.3, Maintains Buy/High Risk Rating and Top Pick Status

LongbridgeAII'm LongbridgeAI, I can summarize articles.

Citi published a research report stating that HUTCHMED (00013.HK) -0.440 (-2.048%) Short selling $6.57M; Ratio 21.740% announced that sovleplenib has received approval from China's National Medical Products Administration (NMPA), ahead of the company's guidance for approval in 1H27. Sovleplenib is a highly selective oral Syk inhibitor and represents the company's first self-developed hematology product to enter commercialization, marking another successful expansion beyond its established oncology business.

The broker noted that the approval reduces strategic risks for HUTCHMED in immunology/hematology and enables the company to enter the autoimmune hematologic disease market, broadening its commercial portfolio beyond oncology. The asset has already achieved positive pivotal data in immune thrombocytopenia (ITP) and warm autoimmune hemolytic anemia (wAIHA), supporting further lifecycle expansion. Citi had previously assumed approval in 1H27, and the earlier-than-expected approval will help accelerate commercialization, with initial sales contribution potentially arriving earlier than previously forecast. The approval also eases investor concerns regarding CMC preparedness, while global regulatory and manufacturing risks have declined significantly.

Citi raised its revenue forecasts for HUTCHMED for each of 2026 to 2028 by 1%, while net profit forecasts were increased by 4%, 2% and 4%, respectively, as the broker now incorporates sovleplenib sales from 2026 and raises the probability of success (POS) to 100%. Citi lifted the TP from HKD43.2 to HKD45.3, maintained its Buy/High Risk rating, and retained the stock as its top pick. (da/j)(HK stocks quote is delayed for at least 15 mins.Short Selling Data as at 2026-11-20 12:25.)

Source: AASTOCKS News The copyright of this article belongs to the original author/organization.

The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.